|Articles|July 1, 2004

Fighting melanoma

New Orleans - Oblimersen sodium (Genasense), the antisense agent under investigation for advanced malignant melanoma, improved progression-free survival but not overall survival, in a recent phase III trial, Michael J. Millward, M.D. reported here at the annual meeting of the American Society of Clinical Oncology (ASCO).

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


Latest CME